Uploaded April 2026 | Updated September 2026, 1 week ago
Carlo Rinaldi, MA, MD, PhD, University of Oxford, 2024 Oxford-Harrington Rare Disease Scholar, is developing a splice-switching oligonucleotide therapy to target mutant androgen receptor in spinal and bulbar muscular atrophy, aiming to slow disease progression and improve quality of life for affected patients. The Oxford-Harrington Rare Disease Centre is a transatlantic initiative dedicated to accelerating breakthrough treatments and cures for rare diseases. Learn more: OxfordHarrington.org.
Carlo Rinaldi, MA, MD, PhD, University of Oxford, 2024 Oxford-Harrington Rare Disease Scholar, is developing a splice-switching oligonucleotide therapy to target mutant androgen receptor in spinal and bulbar muscular atrophy, aiming to slow disease progression and improve quality of life for affected patients. The Oxford-Harrington Rare Disease Centre is a transatlantic initiative dedicated to accelerating breakthrough treatments and cures for rare diseases. Learn more: OxfordHarrington.org.
